Research Article

You have free access to this content

By-passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping

  1. Chalermchai Mitrpant1,2,
  2. Sue Fletcher1,
  3. Patrick L. Iversen3,
  4. Steve D. Wilton1,*

Article first published online: 12 NOV 2008

DOI: 10.1002/jgm.1265

Issue

The Journal of Gene Medicine

The Journal of Gene Medicine

Volume 11, Issue 1, pages 46–56, January 2009

Additional Information

How to Cite

Mitrpant, C., Fletcher, S., Iversen, P. L. and Wilton, S. D. (2009), By-passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping. J. Gene Med., 11: 46–56. doi: 10.1002/jgm.1265

Author Information

  1. 1

    Centre for Neuromuscular and Neurological Disorders, University of Western Australia, QE II Medical Centre, Nedlands, Australia

  2. 2

    Department of Biochemistry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

  3. 3

    AVI Biopharma, Corvallis, OR, USA

*Centre for Neuromuscular and Neurological Disorders, University of Western Australia, QE II Medical Centre, Nedlands, Western Australia, 6009, Australia.

Publication History

  1. Issue published online: 29 DEC 2008
  2. Article first published online: 12 NOV 2008
  3. Manuscript Accepted: 25 SEP 2008
  4. Manuscript Revised: 2 AUG 2008
  5. Manuscript Received: 29 MAY 2008

Funded by

  • National Institutes of Health. Grant Number: RO1 NS044146
  • Muscular Dystrophy Association USA. Grant Number: MDA3718
  • National Health and Medical Research Council of Australia. Grant Number: 303216

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (515K)

References

  • 1
    Blake DJ, Weir A, Newey SE, et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291–329.
  • 2
    Emery AE. Muscular dystrophy into the new millennium. Neuromuscul Disord 2002; 12: 343–349.
  • 3
    Emery AE. The muscular dystrophies. Lancet 2002; 359: 687–695.
  • 4
    Yan J, Feng J, Buzin CH, et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). Hum Mutat 2004; 23: 203–204.
    Direct Link:
  • 5
    White SJ, Aartsma-Rus A, Flanigan KM, et al. Duplications in the DMD gene. Hum Mutat 2006; 27: 938–945.
    Direct Link:
  • 6
    Deburgrave N, Daoud F, Llense S, et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007; 28: 183–195.
    Direct Link:
  • 7
    Ashton EJ, Yau SC, Deans ZC, et al. Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene. Eur J Hum Genet 2008; 16: 53–61.
  • 8
    Tuffery-Giraud S, Chambert S, Demaille J, et al. Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat 1999; 14: 359–368.
    Direct Link:
  • 9
    Bosone I, Bortolotto S, Mongini T, et al. Late onset and very mild course of Xp21 Becker type muscular dystrophy. Clin Neuropathol 2001; 20: 196–199.
  • 10
    Heald A, Anderson LV, Bushby KM, et al. Becker muscular dystrophy with onset after 60 years. Neurology 1994; 44: 2388–2390.
  • 11
    Jennekens FG, ten Kate LP, de Visser M, et al. Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic dystrophy. Neuromuscul Disord 1991; 1: 389–391.
  • 12
    Prior TW, Bartolo C, Papp AC, et al. Nonsense mutations in a Becker muscular dystrophy and an intermediate patient. Hum Mutat 1996; 7: 72–75.
    Direct Link:
  • 13
    Dunckley MG, Manoharan M, Villiet P, et al. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7: 1083–1090.
  • 14
    Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9: 330–338.
  • 15
    Graham IR, Hill VJ, Manoharan M, et al. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 2004; 6: 1149–1158.
    Direct Link:
  • 16
    Sirsi SR, Williams JH, Lutz GJ. Poly (ethylene imine)-poly (ethylene glycol) copolymers facilitate efficient delivery of antisense oligonucleotides to nuclei of mature muscle cells of mdx mice. Hum Gene Ther 2005; 16: 1307–1317.
  • 17
    Gebski BL, Mann CJ, Fletcher S, et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12: 1801–1811.
  • 18
    Mann CJ, Honeyman K, McClorey G, et al. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002; 4: 644–654.
    Direct Link:
  • 19
    Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175–177.
  • 20
    Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587–1592.
  • 21
    Fletcher S, Honeyman K, Fall AM, et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006; 8: 207–216.
    Direct Link:
  • 22
    Mitrpant C, Fletcher S, Wilton SD. Personalised genetic intervention for Duchenne muscular dystrophy: Antisense oligomers and exon skipping. Curr Mol Pharm 2008.
  • 23
    Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006; 13: 1677–1685.
  • 24
    Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 2007; 1772: 243–262.
  • 25
    Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87–91.
  • 26
    Chapman VM, Miller DR, Armstrong D, et al. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 1989; 86: 1292–1296.
  • 27
    Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005; 79: 4599–4609.
  • 28
    Yuan J, Stein DA, Lim T, et al. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol 2006; 80: 11510–11519.
  • 29
    Errington SJ, Mann CJ, Fletcher S, et al. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 2003; 5: 518–527.
    Direct Link:
  • 30
    Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275–1287.
  • 31
    Wilton SD, Lim L, Dye D, et al. Bandstab: a PCR-based alternative to cloning PCR products. Biotechniques 1997; 22: 642–645.
  • 32
    Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568–3571.
  • 33
    Smith PJ, Zhang C, Wang J, et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006; 15: 2490–2508.
  • 34
    Morgan JE, Beauchamp JR, Pagel CN, et al. Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994; 162: 486–498.
  • 35
    McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006; 13: 1373–1381.
  • 36
    Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98: 42–47.
  • 37
    Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9: 1009–1014.
  • 38
    Den Dunnen JT, Grootscholten PM, Bakker E, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989; 45: 835–847.
  • 39
    Wilton SD, Fall AM, Harding PL, et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007; 15: 1288–1296.
  • 40
    Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798–810.
  • 41
    Harding PL, Fall AM, Honeyman K, et al. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 2007; 15: 157–166.
  • 42
    McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 1999; 274: 1715–1722.
  • 43
    Gebski BL, Errington SJ, Johnsen RD, et al. Terminal antisense oligonucleotide modifications can enhance induced exon skipping. Neuromuscul Disord 2005; 15: 622–629.
  • 44
    McClorey G, Fall AM, Moulton HM, et al. Induced exon skipping in human muscle explants. Neuromusc Disorders 2006; 16: 583–590.
  • 45
    Fall AM, Johnsen R, Honeyman K, et al. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 2006; 4: 3.
  • 46
    Adams AM, Harding PL, Iversen PL, et al. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 2007; 8: 57.
View Full Article with Supporting Information (HTML) Get PDF (515K)